Cinnarizine
As of the edition of 20 October 2026, Cinnarizine is a small molecule: marketed, first approved in 1968 (CH); acts on CACNA1C, CACNA1D and CACNA1F and 2 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1975
- Kind
- Small molecule
- Brand name
- Stugeron
- First approved
- 5 June 1968 (CH)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Laboratorio Stada S.L.; 2 holders in all
- Registered trials
- 3, 0 stopped early
- Disease areas
- Hormones; Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| CACNA1F | Voltage-dependent L-type calcium channel subunit alpha-1F | O60840 |
| HRH1 | Histamine H1 receptor | P35367 |
| CACNA1D | Voltage-dependent L-type calcium channel subunit alpha-1D | Q01668 |
| CACNA1S | Voltage-dependent L-type calcium channel subunit alpha-1S | Q13698 |
| CACNA1C | Voltage-dependent L-type calcium channel subunit alpha-1C | Q13936 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 3 |